A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CFZ533 in Healthy Subjects and Rheumatoid Arthritis Patients
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs Iscalimab (Primary) ; Iscalimab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man
- Sponsors Novartis
- 24 Oct 2019 Results published in the American Journal of Transplantation
- 14 Mar 2017 Status changed from recruiting to completed.
- 07 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.